One limitation of our study is that although we validated the requirement of TBC1D24 and SV2B for efficient ADE in multiple cell lines, we were unable to confirm our findings in primary cells due to difficulty in maintaining cell viability following CRISPR editing and subsequent infection via ADE. The gene discussed is TBC1D24; the disease is infection.